SERPINA1 and alpha 1-antitrypsin deficiency: The augmentation therapy with pooled human plasma AAT was introduced in 1988 based on biochemical data showing that intravenous infusions of AAT neutralize NE activity within the lungs of emphysema patients with inherited AATD (Wewers et al., 1987).